Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00828867 |
This is a first time in human (FTIH) study of single escalating doses of investigational study drug to investigate safety, tolerability, and pharmacokinetics in healthy subjects
Condition | Intervention | Phase |
---|---|---|
Healthy Subjects |
Drug: 2000 mg GSK investigational drug Drug: selected dose fed GSK investigational drug Drug: 800 mg GSK investigational drug Drug: 200 mg GSK investigational drug Drug: 100 mg GSK investigational drug Drug: 1500 mg GSK investigational drug Drug: 400 mg GSK investigational drug |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Single Group Assignment, Safety Study |
Official Title: | A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Investigational Study Drug in Healthy Subjects |
Estimated Enrollment: | 41 |
Study Start Date: | November 2008 |
Estimated Study Completion Date: | February 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Cohort 4: Experimental |
Drug: 800 mg GSK investigational drug
NA
|
Cohort 1: Experimental |
Drug: 100 mg GSK investigational drug
NA
|
Cohort 6: Experimental |
Drug: 2000 mg GSK investigational drug
NA
|
Cohort 2: Experimental |
Drug: 200 mg GSK investigational drug
NA
|
Cohort 3: Experimental |
Drug: 400 mg GSK investigational drug
NA
|
Cohort 5: Experimental |
Drug: 1500 mg GSK investigational drug
NA
|
Cohort 7: Experimental |
Drug: selected dose fed GSK investigational drug
NA
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males), or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). A standard unit is defined as 10g ethanol which is equivalent to 100mL wine, 250mL full strength beer, 470mL light beer, 30mL spirits
Contact: US GSK Clinical Trials Call Center | 877-379-3718 |
Australia, New South Wales | |
GSK Investigational Site | Recruiting |
Randwick, New South Wales, Australia, 2031 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 111341 |
Study First Received: | December 8, 2008 |
Last Updated: | June 4, 2009 |
ClinicalTrials.gov Identifier: | NCT00828867 History of Changes |
Health Authority: | Australia: Medicines Australia |
FTIH, single dose, food effect, healthy subjects, double-blind |
Healthy |